N@N

ARIAD to Webcast Conference Call on Second Quarter 2010 Financial Results

_{//health-fitness.news-articles.net/content/2010/ .. ll-on-second-quarter-2010-financial-results.html}
^{Published in Health and Fitness on Wednesday, July 21st 2010 at 5:07 GMT by Market Wire}  

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that it will hold a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Wednesday, August 4, 2010. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior management will discuss the Companya™s financial results as of June 30, 2010, key corporate objectives and additional corporate activities. The Company will announce the highlights of these topics in a press release to be issued before the market opens on August 4, 2010 prior to the conference call.

The live webcast can be accessed by visiting the investor relations section of the Companya™s website at [ http://investor.ariad.com ]. The call can be accessed by dialing 866-831-6224 (domestic) or 617-213-8853 (international) five minutes prior to the start time and providing the pass code 85617427. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks.

About ARIAD

ARIADa™s vision is to transform the lives of cancer patients with breakthrough medicines. The Companya™s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need a" aggressive cancers where current therapies are inadequate. ARIADa™s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck and is in Phase 3 clinical development in patients with advanced sarcomas. ARIADa™s second internally discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia. For additional information about the Company, please visit [ http://www.ariad.com ].